CR10787A - Substituted pyrazole and triazole compounds as ksp inhibitors - Google Patents

Substituted pyrazole and triazole compounds as ksp inhibitors

Info

Publication number
CR10787A
CR10787A CR10787A CR10787A CR10787A CR 10787 A CR10787 A CR 10787A CR 10787 A CR10787 A CR 10787A CR 10787 A CR10787 A CR 10787A CR 10787 A CR10787 A CR 10787A
Authority
CR
Costa Rica
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
ksp
inhibitors
Prior art date
Application number
CR10787A
Other languages
English (en)
Inventor
Yi Xia
Kris G Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Paul A Renhowe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR10787A publication Critical patent/CR10787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR10787A 2006-11-13 2009-05-08 Substituted pyrazole and triazole compounds as ksp inhibitors CR10787A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
CR10787A true CR10787A (es) 2009-07-02

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10787A CR10787A (es) 2006-11-13 2009-05-08 Substituted pyrazole and triazole compounds as ksp inhibitors

Country Status (32)

Country Link
US (2) US8129358B2 (es)
EP (1) EP2091926B1 (es)
JP (1) JP5264755B2 (es)
KR (1) KR20090081020A (es)
CN (1) CN101558049B (es)
AR (1) AR063805A1 (es)
AU (1) AU2007323998B2 (es)
BR (1) BRPI0719002A2 (es)
CA (1) CA2668661A1 (es)
CL (1) CL2007003272A1 (es)
CO (1) CO6382171A2 (es)
CR (1) CR10787A (es)
DO (1) DOP2009000106A (es)
EA (1) EA017748B1 (es)
EC (1) ECSP099326A (es)
ES (1) ES2557478T3 (es)
GE (1) GEP20125389B (es)
GT (1) GT200900122A (es)
HN (1) HN2009000968A (es)
IL (1) IL198471A0 (es)
MA (1) MA30959B1 (es)
MX (1) MX2009005071A (es)
NI (1) NI200900084A (es)
NO (1) NO20092226L (es)
NZ (1) NZ576640A (es)
PE (1) PE20081169A1 (es)
SM (1) SMP200900045B (es)
TN (1) TN2009000178A1 (es)
TW (1) TW200831480A (es)
UA (1) UA97256C2 (es)
WO (1) WO2008063912A1 (es)
ZA (1) ZA200902940B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
US8546434B2 (en) * 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
CA2892919A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP3077376B1 (en) 2013-12-04 2019-10-16 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3386973B1 (en) * 2015-12-11 2020-08-12 Syngenta Participations AG Pesticidally active 1,2,4-triazole derivatives
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
WO2003049679A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US20040259936A1 (en) * 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1503993A4 (en) 2002-05-09 2006-05-03 Cytokinetics Inc COMPOUNDS, METHODS AND COMPOSITIONS
AU2003290507A1 (en) 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1620092A4 (en) 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1622878A4 (en) 2003-05-15 2008-04-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
PT1732926E (pt) 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
JP2008502721A (ja) * 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 分裂キネシンインヒビターとしての置換キノリン誘導体
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
EP1807399A2 (en) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
JP5264755B2 (ja) 2013-08-14
WO2008063912A1 (en) 2008-05-29
HN2009000968A (es) 2011-10-25
MA30959B1 (fr) 2009-12-01
CO6382171A2 (es) 2012-02-15
EP2091926B1 (en) 2015-10-21
ECSP099326A (es) 2009-06-30
CN101558049A (zh) 2009-10-14
PE20081169A1 (es) 2008-09-24
US20080200462A1 (en) 2008-08-21
AR063805A1 (es) 2009-02-18
DOP2009000106A (es) 2009-05-31
KR20090081020A (ko) 2009-07-27
SMP200900045B (it) 2010-03-01
TW200831480A (en) 2008-08-01
AU2007323998A1 (en) 2008-05-29
US8129358B2 (en) 2012-03-06
GEP20125389B (en) 2012-01-25
BRPI0719002A2 (pt) 2013-12-17
NI200900084A (es) 2010-01-29
SMAP200900045A (it) 2009-07-14
EA200900631A1 (ru) 2009-12-30
EA017748B1 (ru) 2013-02-28
CL2007003272A1 (es) 2008-03-24
NZ576640A (en) 2011-10-28
JP2010509365A (ja) 2010-03-25
NO20092226L (no) 2009-08-12
MX2009005071A (es) 2009-05-25
AU2007323998B2 (en) 2011-09-22
CA2668661A1 (en) 2008-05-29
GT200900122A (es) 2011-09-14
CN101558049B (zh) 2012-08-15
TN2009000178A1 (en) 2010-10-18
IL198471A0 (en) 2010-02-17
US7902240B2 (en) 2011-03-08
ES2557478T3 (es) 2016-01-26
EP2091926A1 (en) 2009-08-26
ZA200902940B (en) 2010-05-26
US20100034813A1 (en) 2010-02-11
UA97256C2 (ru) 2012-01-25

Similar Documents

Publication Publication Date Title
HUS2000049I1 (hu) Kináz aktivitással rendelkezõ helyettesített imidazol származékok
SMAP200900045A (it) Composti di pirazolo e triazolo sostituiti come inibitori di ksp
DK2027096T3 (da) Substituerede arylimidazoloner og -triazoloner som inhibitorer for vasopressinreceptorerne
EP2038272B8 (en) Pyridinonyl pdk1 inhibitors
AP2010005167A0 (en) Pyrazole compounds and their use as RAF inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
NO345061B1 (no) Anvendelse av DPP-IV inhibitorer
IL193482A0 (en) Hydantoin based kinase inhibitors
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
ZA200807632B (en) Heterobicyclic pyrazole compounds and methods of use
SI2383271T1 (sl) Aminokinoloni kot inhibitorji gsk-3
EP1988083A4 (en) triazole
DK2066662T3 (da) Serinhydrolaseinhibitorer
EP2084135A4 (en) PYRAZOLES
GB0622084D0 (en) Inhibitors of HSP90
PL1912972T3 (pl) Podstawione związki imidazolowe jako inhibitory KSP
ZA200906423B (en) Pyrazolone derivatives as PDE4 inhibitors
ZA200900625B (en) Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)